AGIO - Agios Pharmaceuticals Inc.

-

$undefined

N/A

(N/A)

Agios Pharmaceuticals Inc. NasdaqGS:AGIO Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Location: 88 Sidney Street, Cambridge, MA, 02139, United States | Website: https://www.agios.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

849.5M

Cash

893.4M

Avg Qtr Burn

-100.4M

Short % of Float

7.66%

Insider Ownership

1.60%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

PDUFA

Approval decision

NDA

Submission

Phase 3

Data readout

Tebapivat (AG-946) Details
Myelodysplastic syndrome

Phase 2b

Update

Tebapivat Details
Sickle cell disease, Blood disorder

Phase 2

Initiation

AG-181 Details
Phenylketonuria

Phase 1

Data readout

AG-236 Details
Polycythemia vera

IND

Submission